Eli Lilly sues four companies over compounded tirzepatide
The lawsuits against four sellers of compounded tirzepatide are part of a widening legal fight that could affect which versions of the drug patients can find.
Eli Lilly and Co. sued Willow Health Services and three other companies, accusing them of selling unapproved compounded tirzepatide products for weight loss without FDA approval or proper testing, according to a report published April 25, 2025 by the legal trade publication Texas Lawyer [1]. The cases were filed in federal courts in New Jersey and California [1].
Tirzepatide is the active ingredient in Lilly's Mounjaro, which is approved to treat type 2 diabetes, and Zepbound, which is approved for weight management [1]. The report describes the filings as a "slew of lawsuits" over the two drugs and says disputes over weight-loss medicines "are landing on court dockets" [1].
The report names Willow Health Services as one defendant and says three other companies were also sued, but it does not identify those three [1]. It also does not give a total count of complaints, a dollar amount Lilly is seeking, or a schedule of court dates [1]. No response from any of the defendants has been reported [1].
The report's coverage is based on a complaint filed against Willow Health Services in federal court, which it links to directly [1]. Lilly's central allegation is that the companies sold compounded tirzepatide "without FDA approval or proper testing" [1]. The suits are accusations; no rulings, settlements or admissions have been reported [1].
It is not yet known how many more suits Lilly plans to file, whether the cases will be consolidated, or whether any of the defendants will challenge the claims in court filings [1].
Why it matters for patients
Tirzepatide sold by compounding pharmacies, telehealth platforms and med spas has become a common alternative for people who cannot get or afford the brand-name products. Lilly's lawsuits target the sellers of those compounded versions, not the patients who use them [1].
If Lilly's campaign expands, the practical effect for patients could be fewer sellers offering compounded tirzepatide, changes in price, or interrupted refills for people whose supplier is named in a case. None of those outcomes has been reported yet [1].
The cases also raise a question patients may care about directly: whether a compounded product they are using was made and tested under the standards the manufacturer says federal law requires [1]. Lilly's claim that the products lacked FDA approval or proper testing is an allegation in a lawsuit, not a finding by a court or regulator [1].
Because the report does not name three of the four defendants, patients cannot yet tell from this filing alone whether any particular pharmacy or platform is involved [1].
What happens next
The report does not list hearing dates, a trial schedule or a timeline for rulings [1]. It also does not say whether Lilly is seeking an injunction that would stop the companies from selling compounded tirzepatide, or only money damages [1]. The identities of the three unnamed defendants and the total scope of the litigation have not been disclosed [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.